期刊
CANCERS
卷 11, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cancers11060802
关键词
liquid biopsy; CTC; prostate cancer; early diagnostic; PSA; radiotherapy
类别
资金
- ERA-NET on Translational Cancer Research TRANSCAN named 'CTC-SCAN' (NCBR) [ERA-NET-TRANSCAN/03/2013]
- FEDER
- Region Languedoc-Roussillon (GEPETOS)
- French National Institute of Cancer
- Innovative Medicines Initiative Joint Undertaking from the European Union's Seventh Framework Programme [115749]
- Innovative Medicines Initiative Joint Undertaking from the EFPIA [115749]
The characterization of circulating tumor cells (CTCs) can lead to a promising strategy for monitoring residual or relapsing prostate cancer (PCa) after local therapy. The aim of this study was to compare three innovative technologies for CTC enumeration in 131 high-risk patients with PCa, before and after radiotherapy, combined with androgen deprivation. The CTC number was tested using the FDA-cleared CellSearch (R) system, the dual fluoro-EPISPOT assay that only detects functional CTCs, and the in vivo CellCollector (R) technology. The highest percentage of CTC-positive patients was detected with the CellCollector (R) (48%) and dual fluoro-EPISPOT (42%) assays, while the CellSearch (R) system presented the lowest rate (14%). Although the concordance among methods was only 23%, the cumulative positivity rate was 79%. A matched-pair analysis of the samples before, and after, treatment suggested a trend toward a decrease in CTC count after treatment with all methods. CTC tended to be positivity correlated with age for the fluoro-EPISPOT assay and with PSA level from the data of three assays. Combining different CTC assays improved CTC detection rates in patients with non-metastatic high-risk PCa before and after treatment. Our findings do not support the hypothesis that radiotherapy leads to cancer cell release in the circulation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据